Orchestra Biomed Holdings Stock Price To Earnings To Growth
| OBIO Stock | 5.62 0.11 2.00% |
Orchestra BioMed Holdings fundamentals help investors to digest information that contributes to Orchestra BioMed's financial success or failures. It also enables traders to predict the movement of Orchestra Stock. The fundamental analysis module provides a way to measure Orchestra BioMed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orchestra BioMed stock.
Orchestra | Price To Earnings To Growth |
Orchestra BioMed Holdings Company Price To Earnings To Growth Analysis
Orchestra BioMed's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Orchestra Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Orchestra BioMed is extremely important. It helps to project a fair market value of Orchestra Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Orchestra BioMed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Orchestra BioMed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Orchestra BioMed's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Orchestra Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Orchestra BioMed Holdings has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Orchestra Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orchestra BioMed's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orchestra BioMed could also be used in its relative valuation, which is a method of valuing Orchestra BioMed by comparing valuation metrics of similar companies.Orchestra BioMed is currently under evaluation in price to earnings to growth category among its peers.
Orchestra BioMed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Orchestra BioMed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Orchestra BioMed's managers, analysts, and investors.Environmental | Governance | Social |
Orchestra Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (16.56) % | ||||
| Current Valuation | 143.33 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 22.05 % | ||||
| Shares Owned By Institutions | 54.90 % | ||||
| Number Of Shares Shorted | 769.71 K | ||||
| Price To Book | 4.60 X | ||||
| Price To Sales | 80.31 X | ||||
| Revenue | 2.76 M | ||||
| EBITDA | (51.22 M) | ||||
| Net Income | (49.12 M) | ||||
| Total Debt | 1.69 M | ||||
| Book Value Per Share | 1.22 X | ||||
| Cash Flow From Operations | (46.13 M) | ||||
| Short Ratio | 12.51 X | ||||
| Earnings Per Share | (1.60) X | ||||
| Target Price | 15.6 | ||||
| Number Of Employees | 56 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 212.57 M | ||||
| Total Asset | 95.21 M | ||||
| Retained Earnings | (248.85 M) | ||||
| Working Capital | 77.91 M | ||||
| Net Asset | 95.21 M |
About Orchestra BioMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orchestra BioMed Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orchestra BioMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orchestra BioMed Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Orchestra BioMed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.Moving against Orchestra Stock
| 0.59 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.46 | LLY | Eli Lilly | PairCorr |
| 0.43 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Orchestra BioMed Piotroski F Score and Orchestra BioMed Altman Z Score analysis. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.